As a doctor specializing in renal tumor treatment, I need to update the knowledge and information of renal tumor treatment in real time. I pay attention to the latest international and domestic treatment progress of renal tumor every day, and I will be glad to have even a little breakthrough in diagnosis or treatment. I have to read a lot of international literature on kidney tumor diagnosis and treatment every day to keep my knowledge system updated. In order to let more patients know the latest information of kidney tumor treatment, I will share this information and my treatment experience with kidney tumor patients from time to time. A US study reported that long-term use of non-aspirin anti-inflammatory analgesics increased the risk of kidney cancer through a 16-year follow-up of 77,525 women and 20-year follow-up of 49,403 men. Close examination of the kidney should be performed in patients with long-term use of anti-inflammatory analgesics. Molecular imaging of small renal tumors may be a non-invasive method to understand the biological characteristics of renal tumors at the cellular and subcellular levels, and can also be used to observe the efficacy of targeted therapies for advanced renal tumors, which is a very promising diagnostic modality and more advanced than PET-CT. It is a very promising diagnostic modality, more advanced than the current PET-CT, and well worth waiting for. On January 27, 2012, the U.S. FDA approved the marketing of Axitinib, a new drug for the treatment of advanced kidney cancer, which is manufactured by Pfizer, Inc. Axitinib is the seventh targeted therapy for the treatment of advanced kidney cancer since the first targeted therapy was launched in 2005. This drug is mainly used in the second-line treatment of advanced kidney cancer, which can provide more drug treatment options for patients with advanced kidney cancer. There are two main types of targeted therapies that have been marketed in the past six years, one acting on the receptor for vascular endothelial growth (VEGF), the main drugs are sorafenib sorafenib (Nexavar, 2005), sunitinib sotanib (Sutent, 2006), pazopanib (Votrient, 2009) . The other class is VEGF antibodies, the main drugs being bevacizumab (Avastin, 2009); temsirolimus (Torisel, 2007) and everolimus (Afinitor, 2009) target rapamycin (mTOR). Axitinib is a small molecule tyrosine kinase inhibitor that acts on multiple targets of the receptor, including the VEGF receptor 1, 2 and 3 targets. Axitinib phase III clinical trial was mainly selected as a randomized controlled study of sorafenib, and the results showed that Axitinib prolonged progression-free survival time by 2 months compared to sorafenib, and the side effects of the two drugs were basically similar mainly diarrhea, hypertension, fatigue, anemia, decreased appetite, vomiting, and skin reactions. However, Axitinib is more common than Sorafenib in gastrointestinal tract, hypothyroidism, hypertension, vocal difficulties, and less common than Sorafenib in anemia and skin reactions. According to FDA recommendations, blood pressure should be controlled before taking the drug, and uncontrolled brain metastases and gastrointestinal bleeding are contraindicated for this drug. The only drugs currently available in China are sorafenib and sotanex, and this drug is not yet available in China. New York (Reuters Health) March 13, citing an article in the American Journal of Urology, showed that the success rate of radiofrequency ablation (RFA) is closely related to the size of the kidney tumor. Radiofrequency ablation (RFA) of kidney tumors smaller than 3 cm is very effective, with success rates equivalent to partial nephrectomy, and RF ablation of kidney tumors larger than 3 cm is less effective than partial nephrectomy. Data from the University of Texas study showed that long-term follow-up of 159 renal tumors treated with radiofrequency ablation had a mean tumor size of 2.4 cm (range 0.9 – 5.4 cm) and a median follow-up of 54 months (range 1.5 – 120 months). Pre-ablation biopsy confirmed 150 tumors (94%), including 108 renal cell carcinomas (72%), 10 vascular smooth muscle lipomas (7%), 18 eosinophilic tumors (12%), 4 benign tissues (3%), and oncocytic tumors (1%). The results showed that the 3-year tumor-free survival (DFS) was 92% for all patients, 96% for 3-year DFS and 95% for 5-year DFS for patients with tumors smaller than 3.0 cm, and 79% for 3-year DFS and 79% for 5-year DFS for patients with tumors larger than 3.0 cm, which were statistically significantly different. Treatment failure in patients with tumors larger than 3.0 cm was due to local recurrence and incomplete ablation, which was achieved by re-ablation, but they suggested that recurrent cases could also be treated by surgical resection. For renal tumors less than 3 cm radiofrequency ablation can achieve both the therapeutic effect of tumor removal and significantly reduce the trauma of surgery. The first phase III trial comparing axitinib with sorafenib in the first-line treatment of metastatic renal cell carcinoma (mRCC) showed that the results of axitinib were better than those of sorafenib, but not enough to conclude that it was “better” than sorafenib. Adverse effects of diarrhea, hypertension, weight loss, decreased appetite, dysphonia, increased hemoglobin, hypothyroidism, hypercalcemia and abnormal laboratory findings were more common in the axitinib group. In contrast, hand-foot syndrome, hypocalcemia, hypophosphatemia, and anemia occurred more commonly in the sorafenib group. Axitinib was approved by the FDA on January 27, 2012 for use in advanced renal cancer (Renal Cell Carcinoma (RCC)) that has failed to respond to other systemic therapies. Axitinib, developed by Pfizer under the trade name Inlyta, is a multi-targeted tyrosine kinase inhibitor similar to Pfizer’s other anti-cancer drug Sunitinib, which inhibits the Vascular Endothelial Growth Factor Receptor (VEGFR) Receptor (VEGFR) VEGFR1, VEGFR2, VEGFR3, Platelet-derived growth factor receptor (PDGFR), and c-KIT. 2. A large retrospective cohort study in the United States showed that an increasing number of patients with small renal masses (SRCs) are being followed up with a follow-up study. A large retrospective cohort study in the United States showed that an increasing number of patients with small renal masses (SRCs) are using follow-up monitoring as an initial treatment strategy. In older patients with this type of disease, follow-up surveillance does not adversely affect kidney cancer-specific survival, whereas surgical treatment may be associated with an increased risk of cardiovascular (CV) complications and all-cause mortality. Therefore, follow-up surveillance may be considered in patients with small renal masses who are not candidates for surgical treatment.